Update on overall survival (OS) of RESCUE: An open-label, phase 2 trial of camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (HCC).
Yun Zhang(Harbin Medical University), Quanren Wang(Jiangsu Hengrui Medicine (China)), Jian Wu(Sun Yat-sen University), Zhenggang Ren(Ministry of Education of the People's Republic of China), Xianhai Mao(Hunan Provincial People's Hospital), Jianping Xiong(Nanchang University), Shanzhi Gu(Central South University), Yanqiao Zhang(Harbin Medical University), Lihua Wu(Zhejiang University), Zhiming Wang(Guangzhou University of Chinese Medicine), Jie Shen(Xinjiang Medical University), Jianming Xu(Chinese PLA General Hospital), Jingfeng Liu(Fujian Medical University), Le‐Qun Li(Shanghai Sixth People's Hospital), Guoliang Shao(Zhejiang Cancer Hospital), Jiayin Yang(Saudi Center for Organ Transplantation), Ling Zhang(Fujian Medical University), Li Xu(Fujian Medical University), Tao Yin(Rutgers, The State University of New Jersey)
Cited by 10
Related Papers
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k